Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
67
resultados
Última actualización
05/04/2026 [07:55:00]
Resumen de: US20260092920A1
The present invention discloses use of an agent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing a neurodegenerative disease in a subject, wherein the level of DDR2 in a sample from the subject being higher than the level of a control not having the disease indicates that the subject has the neurodegenerative disease. The present invention also discloses a kit and a method for diagnosing a neurodegenerative disease, and a computer-readable storage medium. The present invention can efficiently and accurately diagnose the neurodegenerative disease by detecting DDR2.
Resumen de: US20260092326A1
Biomarkers and methods for identifying, verifying and confirming circulating serum-based microRNAs. The microRNAs (PARKmiRs) can be used to differentiate patient's suffering from Alzheimer's disease (AD) from non-AD patients.
Resumen de: US20260091025A1
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.
Resumen de: US20260092931A1
Diagnostic and therapeutic methods for neurodegenerative diseases. Are provided involving assaying abnormal proteins (hyperphosphorylated tau, α-synuclein, TDP-43) associated with neuronal turnover inhibition or promotion in patient samples. Abnormal protein expression and apoptotic activity are detected, aiding disease progression assessment. Therapeutically, a method is provided for treating neurodegenerative diseases, administering compounds promoting neuronal turnover or modulating proteins involved in the process. The invention extends to identifying suitable drugs, employing neuronal turnover induction, miRNA modulation, and protein activity inhibition or enhancement. The claims also encompass various species, tissues, and cultured cells. Furthermore, the invention is applicable to diverse neurodegenerative diseases with abnormal protein accumulation, presenting novel diagnostic and treatment approaches.
Resumen de: AU2024277300A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: WO2025018933A1
The present embodiments relate to an immunoassay kit capable of measuring p-tau205 in a sample and to methods involving the use of such an immunoassay kit. The present embodiment also relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to p-tau205 and that can be used in such an immunoassay kit.
Resumen de: US20260083826A1
The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and/or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.
Resumen de: WO2026064441A1
The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42/40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS/MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42/40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.
Resumen de: CN121152975A
The present invention relates to the use of biomarkers for measuring the efficacy or effectiveness of a treatment for neurodegenerative diseases, in particular Alzheimer's disease.
Resumen de: AU2024277300A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: US20260008840A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: AU2026201500A1
Abstract Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: CN121399472A
The present invention relates to a nasal fluid sample obtained from a subject, the nasal fluid sample comprising one or more marker protein amyloid beta (A beta), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for use in a method for aiding in the diagnosis of a degenerative disease of the nervous system, and to the use of a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for aiding in the diagnosis of a degenerative disease of the nervous system. The invention further relates to a method for aiding the diagnosis of a nervous system degenerative disease in a subject/individual.
Resumen de: MX2022001817A
The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R- tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.
Resumen de: AU2024366503A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
Resumen de: WO2026055671A1
Provided herein are anti-Siglec-10 and Siglec-8 antibody compositions and combinations thereof, and their use in the treatment of neurodegenerative diseases.
Resumen de: WO2026055173A1
The present invention provides a method for identifying a subject having a stabilized circulating peptide. The method comprises detecting the stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from the subject. The method may further comprise treating a neurodegenerative disease, or monitoring or adjusting a treatment of a neurodegenerative disease. Also provided is a kit. The kit comprises a binding protein that specifically binds a stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from a subject. The kit may further comprise an agent for detecting, treating or monitoring a neurodegenerative disease in the subject. The neurodegenerative disease may be Alzheimer disease.
Resumen de: WO2026051874A1
Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and/or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.
Resumen de: US20260072043A1
The present disclosure provides methods for diagnosing or determining susceptibility to Alzheimer's Disease a subject by obtaining a biological sample from the subject; detecting one or more biomarkers in the biological sample selected from the group consisting of: inflammation biomarkers, oxidative stress biomarkers, insulin resistance biomarkers, and autophagy biomarkers; and diagnosing the subject with Alzheimer's Disease where one or more of the biomarkers is detected in the biological sample. Also provided are methods of treating a subject with Alzheimer's Disease comprising administering to the subject an effective amount of one or more agents for the treatment of inflammation, oxidative stress, insulin resistance, and/or autophagy.
Resumen de: US20260072040A1
The invention relates to methods and uses of cell free histone H3 isoforms H3.1, H13.2, H3t and/or H3.3 (or cell free nucleosomes containing said isoforms) of determining the origin of a cell free histone or cell free nucleosome in a body fluid sample as originating from a dividing or non-dividing cell.
Resumen de: CN121039498A
The present invention relates to a method for the in vitro diagnosis of a neurodegenerative disease in a human or animal individual in the early stage, comprising a step comprising the detection of the presence of at least one marker selected from the group consisting of derived forms of amyloid beta (A beta) peptides, the derivative forms are selected from oligomers of the peptide and pre-fibrotic and fibrotic aggregated forms of the peptide, and derivative forms of a phosphorylated tau protein, and the derivative forms are selected from over-phosphorylated forms of the protein, aggregated forms of the protein and modified phosphorylated tau proteins resulting from one or more post-translational modifications; the presence of a marker is detected in a fecal sample of the individual.
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Nº publicación: CN121620700A 06/03/2026
Solicitante:
分子优公司
Resumen de: AU2024276342A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
BOPI
Sede Electrónica
